Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Semax peptide: does it work, is it legal, and what does it cost?

Nasal peptide registered in Russia; rodent and Russian stroke trial data; not FDA approved; nasal use in HHS's October 2026 draft policy.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Quick answers

Quick answers about Semax
Does it work in people?Evidence: Human observational evidence

Limited human studies; none strong enough for a higher grade. See the evidence

Is it legal?Regulatory: HHS interim policy (draft)

Not FDA approved. HHS's draft policy covers single-ingredient compounding under strict conditions. Blends are not covered. [10] [11] See legal status

What does it cost?No FDA approved product and no verified compounded price. Insurance does not cover it. See cost by channel
Side effects?No systematic safety data from blinded trials. Nasal irritation reported with intranasal use. Anxiety, irritability, or insomnia reported anecdotally with higher doses. See side effects and interactions
Tested athlete?WADA: WADA status unclear

What is Semax?

Semax is a seven amino acid fragment of the stress hormone ACTH, modified to have no hormonal activity, developed in Moscow and registered in Russia as nasal drops for stroke, cognitive impairment, and optic nerve disease. Rodent studies show it raises BDNF (a protein that supports nerve cell growth) and its receptor in the hippocampus, the brain's memory center, and Russian clinical studies from the 1990s onward report better recovery after ischemic stroke (stroke from a blocked artery), but those trials are open label (everyone knew who was treated), published in Russian, and not independently replicated. It was on the 503A Category 2 list (compounding ingredients flagged for significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn. At the July 2026 Pharmacy Compounding Advisory Committee meeting on adding it to the 503A bulks list (ingredients pharmacies may use to compound drugs for individual patients), FDA's drug center recommended against listing and the committee voted in favor, according to HHS. On October 28, 2026 HHS released a draft enforcement discretion policy: HHS says it does not intend to take enforcement action against licensed pharmacies and physicians that compound single-ingredient semax as a nasal product only on a patient-specific prescription, under strict quality and reporting conditions. The draft policy is not an FDA approval, does not add semax to the bulks list, and does not change its evidence grade.

Semax is a synthetic heptapeptide analog of ACTH fragment 4-10 (Met-Glu-His-Phe-Pro-Gly-Pro), a melanocortin derived nootropic and neuroprotective peptide. It is also known as Met-Glu-His-Phe-Pro-Gly-Pro, ACTH(4-7)-Pro-Gly-Pro, Semax 0.1% and 1% nasal drops, N-acetyl Semax and NA-Semax amidate (unstudied analogs), Semax peptide, Semax nasal spray, Semax nasal drops.

How does it work?

Semax is derived from ACTH(4-10) with a C-terminal Pro-Gly-Pro that protects it from breakdown. It does not stimulate cortisol release. In rat hippocampus a single intranasal dose increased BDNF protein and trkB receptor expression within hours, and rodent work also shows effects on the serotonergic and dopaminergic systems, reduced nitric oxide production after ischemia, and increased expression of neurotrophic and immune genes. Intranasal delivery is proposed to reach the brain along olfactory pathways. Human mechanistic data are limited.

Key facts
ClusterCognitive and neuroprotective
RoutesIntranasal drops (Russian product and most sold forms); Subcutaneous injection (as sold, no published human data)
Conditions studiedCognitive decline and nootropic use; Depression; Stroke recovery
Recordv3, reviewed, verified Nov 1, 2026

Semax benefits: what the evidence shows

Evidence: Human observational evidenceGrade assigned per the methodology.

Human evidence consists of Russian clinical trials that are open label or poorly described, published in Russian language journals. Gusev et al. 1997 reported faster neurological recovery and lower mortality in acute hemispheric ischemic stroke patients given intranasal semax alongside standard care compared with controls. Gusev et al. 2005 reported fewer exacerbations in chronic cerebrovascular insufficiency, and Gusev et al. 2018 reported benefits at several stages of ischemic stroke. None used a placebo controlled double blind design described in an indexed English language report, and none have independent replication. Animal data on BDNF induction are more rigorous. PeptideAgent grades the evidence human observational.

Indexed studies by evidence grade
Evidence typeIndexed studiesParticipants (human)
Human randomized trials0n/a
Human observational studies3n/a
Animal studies1n/a
All indexed studies4n/a

Human evidence

Gusev 1997: patients in the acute period of hemispheric ischemic stroke received intranasal semax (12 to 18 mg per day) with standard therapy; the authors report faster regression of neurological deficit and improved EEG parameters versus standard therapy alone. Gusev 2005: patients with chronic cerebrovascular insufficiency treated with semax courses had fewer exacerbations over follow up. Gusev 2018: an analysis across stages of ischemic stroke reporting improved functional outcomes. These are open comparative studies without blinding or placebo, from the developing research group.

Animal evidence

Dolotov et al. 2006: intranasal semax in rats increased hippocampal BDNF protein about 1.4 fold and trkB expression within hours of a single dose. Other rodent studies from the Institute of Molecular Genetics report reduced infarct volume after focal ischemia, changes in expression of hundreds of genes involved in inflammation and neurotransmission, and improved learning in behavioral tests.

Key studies

Indexed studies of Semax
StudyDesign and populationOutcomeGrade
Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus2006 PMID 16996037Rat study of intranasal peptide administrationRatsSingle intranasal dose increased hippocampal BDNF protein and trkB expression within hoursEvidence: Animal-only evidence
Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)1997 PMID 11517472Open comparative clinical study, Russian languageAdults in the acute period of hemispheric ischemic strokeFaster regression of neurological deficit and improved EEG measures with intranasal semax added to standard therapy; not blinded or placebo controlledEvidence: Human observational evidence
Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency2005 PMID 15792140Open comparative clinical study, Russian languageAdults with chronic cerebrovascular insufficiencyFewer exacerbations and slower progression reported with semax courses; not blindedEvidence: Human observational evidence
The efficacy of semax in the treatment of patients at different stages of ischemic stroke2018 PMID 29798983Open comparative clinical study, Russian languageAdults at acute, early recovery, and late recovery stages of ischemic strokeImproved functional recovery reported with semax across stages; not blinded or placebo controlledEvidence: Human observational evidence

Conditions studied

Conditions with evidence for Semax
ConditionGradeNote
Cognitive decline and nootropic useEvidence: Human observational evidenceApproved in Russia; Russian clinical reports; no indexed RCT; FDA's drug center recommended against 503A listing and the advisory committee voted in favor (HHS policy, Appendix B); HHS's October 2026 draft policy, which is not an approval, covers conditional compounding of the single-ingredient product.
DepressionEvidence: Animal-only evidenceRaised BDNF in rat hippocampus after a single dose; no human depression study.
Stroke recoveryEvidence: Human observational evidenceUnblinded Russian studies reported faster neurological recovery when added to standard care; approved in Russia only; FDA's drug center recommended against 503A listing and the advisory committee voted in favor (HHS policy, Appendix B); HHS's October 2026 draft policy, which is not an approval, covers conditional compounding of the single-ingredient product.

Is Semax legal in the United States?

Regulatory: HHS interim policy (draft)WADA: WADA status unclear

FDA and compounding status

Semax is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 24, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds semax when every condition is met: a single active ingredient only (no blends or stacks), the allowed route (intranasal only), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add semax to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.

WADA status

WADA status unclear. The current prohibited list does not name this compound explicitly and its class status is not settled. Athletes should ask their anti-doping organization before use.

Regulatory timeline

  1. HHS

    HHS draft policy lets licensed pharmacies compound six peptides without enforcement action

    HHS Secretary Robert F. Kennedy Jr. announced a draft enforcement discretion policy (FR Doc. 2026-22192, filed October 28 and published in the Federal Register on October 30, 2026). HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157, epitalon, KPV, MOTS-c, semax, or TB-500, if the product contains a single active ingredient, uses an allowed route, is made from an FDA-registered manufacturer's substance with a tested certificate of analysis, carries a patient-specific prescription, and serious adverse events are reported to FDA. It is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Comments are open through November 13, 2026 on Docket HHS-OASH-2026-0496.

  2. PCAC

    FDA advisory committee reviews six peptides; FDA's briefing recommends against listing

    At its July 23 to 24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon for the 503A bulks list. FDA's own briefing slides proposed not adding any of them. The committee voted in favor of listing all six, as HHS confirmed in its October 2026 peptide policy. The committee is advisory, and FDA proposed no rule, so none of the six was added to the 503A bulks list.

  3. FDA

    FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2

    FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.

  4. FDA

    FDA places a batch of nominated peptides in 503A Category 2

    In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.

Full tracker for Semax or the category-wide tracker.

Email me when Semax's status changes

Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.

What published studies of Semax used

Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.

Russian stroke studies used intranasal semax 12 to 18 mg per day (1% solution) for 5 to 10 days in acute ischemic stroke, and lower doses of the 0.1% solution (roughly 0.2 to 2 mg per day) for cognitive and asthenic indications, according to Russian labeling and open label reports. No dose finding trial has been published in an indexed English language journal.

Routes reported

Routes of administration reported for Semax
#Route
1Intranasal drops (Russian product and most sold forms)
2Subcutaneous injection (as sold, no published human data)

Semax side effects

Side effects

Side effects reported for Semax
#Reported side effect
1No systematic safety data from blinded trials
2Nasal irritation reported with intranasal use
3Anxiety, irritability, or insomnia reported anecdotally with higher doses
4Hair loss reported anecdotally without study confirmation
5Long term safety unknown

Interactions

Interactions reported for Semax
#Interaction
1No formal human interaction studies exist
2Theoretical additive effects with other serotonergic or dopaminergic agents given rodent monoamine data (not tested)

Contraindications

Contraindications for Semax
#Contraindication
1Russian labeling lists acute psychosis, anxiety disorders with agitation, pregnancy, and breastfeeding
2Children (no data outside Russian pediatric reports)
3Competitive athletes should confirm status with their anti-doping organization

How do people access Semax legally?

Typical cost: No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient semax on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.

Access options

  • Conditional

    Compounded access under HHS's draft policy (announced October 28, 2026): HHS says it does not intend to take enforcement action when a state-licensed pharmacy or licensed physician compounds single-ingredient semax as a nasal product only on a patient-specific prescription, under strict quality and reporting conditions. The policy is a draft, is not binding, and HHS may revisit it. Blends and stacks are not covered, and state law still applies.

  • Not available

    Not available as an FDA approved product; registered prescription drug in Russia.

  • Not available

    Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.

Access paths are checked against public regulatory records. Products labeled research use only are never listed.

Compare Semax

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [12] [13] [14]

In October 2026, HHS released a draft policy saying it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds semax as a single-ingredient product as an intranasal product only, on a patient-specific prescription, from an FDA-registered manufacturer with a tested certificate of analysis. It is not an FDA approval and does not put semax on the 503A bulks list; the policy is not binding, and HHS may revisit it. Blends that mix semax with other peptides are not covered, and state rules still apply. [10] [11]

What FDA found

  • July 2026: FDA's review found wellness clinics, concierge services, functional and regenerative medicine clinics, and online retailers in the US marketing semax injections and nasal products. [15]
  • April 2020: FDA named semax among the bulk substances a state-licensed 503A pharmacy compounded outside section 503A. [13]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [12] [16] [17] [18] [19] [20]

What that means for you

  • A pharmacy that compounds semax relies on HHS's draft policy, which has strict conditions and which HHS can revisit, so it carries some regulatory risk. Compounding it outside those conditions, such as in a blend or by another route, has no federal basis. [11]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [20]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [21]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [22] [23]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [18]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, WADA status is unclear; ask your anti-doping organization before any use. [7]

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [20]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [24] [25] [26]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [14] [26] [27]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [20] [28] [29] [30] [31] [32]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [20]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [24]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [14]
  • Pharmacy: Is this made for me on a prescription written in my name? [27]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [14] [26]
  • Prescriber: What is the legal basis for a pharmacy to compound semax? Is it FDA approved or on the 503A bulks list? [5] [20]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [14]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [21]

Frequently asked questions

What is semax peptide used for?

Semax is a synthetic seven amino acid fragment of the stress hormone ACTH. In Russia it is a registered prescription drug given as nasal drops for ischemic stroke (stroke from a blocked artery) and chronic cerebrovascular disease (long term poor blood flow to the brain). In the United States it is not FDA approved and is marketed mainly as a nootropic (a supposed focus and memory enhancer), a use no controlled trial has tested. [2] [3] [5]

Is semax legal in the United States?

It is not an FDA approved drug, but possessing it is not a crime. It was on the 503A Category 2 list from September 2023 until April 22, 2026, when its nomination was withdrawn. At the July 24, 2026 Pharmacy Compounding Advisory Committee meeting, FDA's drug center (CDER) recommended against adding it to the 503A bulks list and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026 HHS released a draft enforcement discretion policy: HHS says it does not intend to take enforcement action against licensed pharmacies and physicians that compound single-ingredient semax as a nasal product only on a patient-specific prescription, under strict quality and reporting conditions. It is a draft, not an approval or a bulks listing, and HHS may revisit it. Blends and stacks are not covered, and state law still applies. It is a registered prescription drug in Russia. [5] [6] [10] [11]

Semax benefits: what does the evidence show?

The claimed benefits rest on two kinds of evidence. In rats, a single intranasal dose raised hippocampal BDNF and its trkB receptor within hours, which is the basis for the cognitive claims. In people, Russian open label studies report faster recovery after ischemic stroke and fewer exacerbations of chronic cerebrovascular disease. There is no blinded placebo controlled trial in an indexed English language journal and no study in healthy adults, so benefits for focus or memory are unproven. PeptideAgent grades the evidence human observational. [1] [2] [3]

Does semax help after a stroke?

Russian trials say yes: Gusev and colleagues reported faster neurological recovery in acute hemispheric ischemic stroke in 1997 and benefits across stroke stages in 2018. These studies were open label, compared semax plus standard care against standard care alone, and came from the group that developed the drug, so the effect has not been confirmed by an independent blinded trial. [2] [4]

How does semax work, and what is its half-life?

Semax is built from the ACTH(4-10) sequence with a Pro-Gly-Pro tail added to slow its breakdown. In rats it increases BDNF and its trkB receptor in the hippocampus, a growth factor pathway tied to learning. No human half-life has been published. In a rat study using labeled semax given into the nose, the peptide reached the brain within 2 minutes and was rapidly broken down by enzymes, with the Pro-Gly-Pro fragment making up most of what remained. [1] [8]

What are the side effects of semax?

No blinded safety trial exists. Nasal irritation is the most common complaint with drops. Anecdotal reports mention anxiety, irritability, insomnia, and hair thinning at higher doses, none confirmed by study. Russian labeling advises against use in acute psychosis and agitated anxiety states and in pregnancy. [3] [4]

How is semax taken?

As nasal drops, the form registered in Russia in 0.1% and 1% strengths and the route used in the published human studies. Injectable versions are sold but have no published human data. Semax is not an approved drug in the United States, so there is no US labeled dose. PeptideAgent does not give doses for unapproved peptides. [2] [3]

Is semax banned by WADA?

Unclear. Semax is not named on the WADA Prohibited List, and because it is an approved drug in Russia it does not automatically fall under section S0 for non-approved substances. It is an ACTH fragment without corticotropic activity, but athletes should confirm with their anti-doping organization before use. [7]

Semax vs selank: what is the difference?

Both are Russian nasal peptides from the same research tradition. Semax is an ACTH fragment marketed for stroke recovery and cognition with rodent BDNF data; selank is a tuftsin analog marketed for anxiety with small Russian trials against benzodiazepines, two of them randomized but unblinded. FDA presented semax to its compounding advisory committee in July 2026 and its own briefing recommended against adding it to the 503A bulks list; selank was not among the peptides FDA presented to the committee in July 2026. Neither has an independent blinded trial. [1] [6]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

From the blog

More on the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Dolotov OV et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res 2006PubMed 16996037, 2006
  2. [2]Gusev EI et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova 1997PubMed 11517472, 1997
  3. [3]Gusev EI et al. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova 2005PubMed 15792140, 2005
  4. [4]Gusev EI et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2018PubMed 29798983, 2018
  5. [5]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  6. [6]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  7. [7]WADA Prohibited ListWADA, 2026
  8. [8]Shevchenko KV et al. Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Bioorg Khim 2006PubMed 16523722, 2006
  9. [9]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
  10. [10]Federal Register notice of availability: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, FR Doc. 2026-22192 (Docket HHS-OASH-2026-0496)Federal Register, 2026

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, November 1). Semax: evidence, legality, and access. https://peptideagent.ai/peptides/semax
HTML link
<a href="https://peptideagent.ai/peptides/semax">Semax: evidence, legality, and access</a>, PeptideAgent, updated November 1, 2026.